Why Is SUMMIT THERAPEUTICS (SMMT) Stock Down Today?
By the Top Tier Newswire AI Desk · November 18, 2026 at 12:09 AM ET · reviewed against 6 wire stories
SUMMIT THERAPEUTICS (SMMT) is down -9.73% in the latest session. Our newswire has captured 6 stories on SMMT across 6 sources in the last 36 hours, with AI sentiment reading bearish (avg 36/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
Summit Therapeutics (SMMT) shares fell 9.73% to $10.67 as the U.S. Food and Drug Administration recommended a new trial for its lung-cancer drug. The regulator’s disclosure was more extensive than the biotech company had previously announced, signaling that the drug needs to prove it can help patients live longer.
What Happened
The FDA declined to approve ivonescimab, one of biotech's most closely watched cancer drugs. The regulator told Summit Therapeutics that the drug must demonstrate an overall survival benefit, not just a progression-free survival benefit. This decision followed the company's submission of a Biologics License Application.
Citigroup maintained its Buy rating on the stock but lowered its price target to $42.00. The move contributed to a broader decline in U.S. indexes on Monday, with Summit Therapeutics falling the furthest among tracked stocks. The company remains unprofitable with a trailing twelve-month earnings per share of negative $1.07.
What The Data Shows
The stock has experienced a sharp decline over the last eight sessions, moving down 34.7% from $16.33 to $10.67. This drop places the share price near the bottom of its 52-week range, which spans from $11.53 to $29.23. On November 17, 2026, the stock printed one fresh 52-week high and 29 fresh 52-week lows.
The company has a market capitalization of $11.3 billion. Revenue over the trailing twelve months is reported at negative 100.0%. Social media sentiment has deteriorated, with the 30-day average score falling to 33 from a previous 43. Retail traders on X are discussing the FDA's rejection, noting the lack of statistically significant overall survival improvement.
What To Watch
Investors will monitor the company's response to the FDA's recommendation for a new trial. The upcoming release of first-line data is also a key factor to watch as the company navigates the regulatory feedback.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
SMMT · Nov 18 session (5-min) · -1.51% vs prior close · updated 8:53 PM ETAI sentiment, last 36h · averaged over 6 stories · 36/100 bearish
The headlines behind the move
Story flow · 6 stories on the wire, last 36h · hover or tap a dot for the headline
2d agoMarketWatchBEARISH 22General
Summit Therapeutics’ stock tumbles again as FDA recommends new trial for lung-cancer drug
The U.S. regulator’s disclosure was more extensive than what the biotech company had announced Sunday.
3d agoMorningstarBEARISH 22General
The FDA declined to approve one of biotech's most closely watched cancer drugs. The company's stock tumbled.
The regulator told Summit Therapeutics that the lung-cancer drug needs to prove it can help people live longer.
3d agoStockTitanNEUTRAL 48General
San Mateo Midstream Prices Upsized Offering of $850 Million of Senior Notes Due 2031
3d agoBarron'sBEARISH 38General
U.S. Indexes Dropped Monday; Summit Therapeutics Fell Furthest
3d agoSeeking AlphaBEARISH 42Analyst
Summit Therapeutics: Still A Hold As The 2L Gamble Fails And 1L Data Looms
Summit Therapeutics remains a
3d agoGuruFocusBEARISH 42Analyst
SMMT Maintained by Citigroup -- Price Target Lowered to $42.00
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →